Because the recent use of HDACIs in advanced CTCL could contribute to excellent outcomes, we hypothesized that HDACIs might inhibit the migration and reduce the CCR6 expression [13–17, 19–22]. Here, CCR6 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.